title: Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
abstract: This report reviews the design and preliminary results of ongoing and new studies that are evaluating novel antiretroviral drug combinations for the treatment of patients with HIV-1 infection. The studies reviewed in this report are: (1) Selection of Thymidine Analogue Regimen Therapy (START) I and II which compare three-drug combinations of stavudine (d4T), lamivudine (3TC), and indinavir, or d4T, didanosine (ddI), and indinavir versus zidovudine (ZDV), 3TC, and indinavir; (2) ATLANTIC, a study that compares d4T and didanosine (ddI) in combination with a third agent, either 3TC, nevirapine, or indinavir; and (3) the OZCOMBO studies: OZCOMBO 1, which compares two-drug combinations of d4T and 3TC, d4T and ddI, and ZDV and 3TC, all in combination with indinavir, and OZCOMBO 2, which compares two-drug combinations of d4T and ddI, ZDV and ddI, and ZDV and 3TC, all in combination with nevirapine. Preliminary results from these studies suggest that novel dual-nucleoside analogue reverse transcriptase inhibitor pairs, d4T and 3TC, d4T and ddI, and ZDV and ddI, as part of three-drug combinations, achieve antiretroviral effects comparable to ZDV- and 3TC-based three-drug combination regimens.
authors.affiliation: Division of International Medicine and Infectious Diseases, Department of Medicine, Cornell University Medical College, New York, New York 10021, USA.
authors.forename: R
authors.initials: R
authors.lastname: Gulick
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017327:Clinical Trials, Phase IV as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D009705:Nucleosides / Q000627:therapeutic use*; D010865:Pilot Projects; D011480:Protease Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D019380:Anti-HIV Agents; D009705:Nucleosides; D011480:Protease Inhibitors